The U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency’s previous guidances for industry to improve clinical trial diversity.
As healthcare companies continue to refine and expand methods of achieving diversity, equity and inclusion, DE&I leaders know their efforts are not a sprint, but part of an ongoing journey.
